Lopicure-AS 75 Capsule contains a combination of Atorvastatin 10 mg and Aspirin 75 mg, formulated to manage cardiovascular risk factors effectively. Atorvastatin, a member of the statin class, acts by inhibiting HMG-CoA reductase, a key enzyme in cholesterol biosynthesis, thereby reducing low-density lipoprotein cholesterol (LDL-C) levels and overall lipid profile improvement. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), leading to decreased thromboxane A2 production and subsequent platelet aggregation inhibition. This dual-action capsule is indicated for the prevention of atherosclerotic cardiovascular disease in patients at high risk, including those with a history of myocardial infarction, stroke, or peripheral arterial disease. It aids in reducing the incidence of major cardiovascular events such as heart attacks and strokes by addressing both hyperlipidemia and thrombosis. Lopicure-AS 75 should be used under medical supervision, with regular monitoring of lipid levels, liver function, and bleeding parameters. Caution is advised in patients with active bleeding, liver impairment, or hypersensitivity to statins or aspirin. The combination therapy offers a convenient and effective approach to cardiovascular risk reduction, enhancing patient compliance and therapeutic outcomes.